Tethys makes new appointments
This article was originally published in Clinica
Executive Summary
Personalised medicine company Tethys Bioscience has promoted Michael Richey to president, with Mohan Iyer taking over his previous role of chief business officer. The firm has also appointed Eric Book, Brian Best and Ted Tarasow to its management team. Mr Richey has been with the Emeryville, California firm since it was founded in 2005, while Mr Iyer joins from Burrill & Company's Merchant Bank, where he was managing director of healthcare investment banking. Dr Book, who has joined Tethys as chief medical officer, was previously senior vice-president and chief medical officer of Blue Shield of California. Mr Best, who will become vice-president of commercial operations at Tethys, has 17 years of industry experience at companies including Medicure Pharma, PDL Biopharma and Millennium Pharmaceuticals. Mr Tarasow, who has been named vice-president of product development and laboratory operations, was previously director of the biosecurity and nanosciences lab at Lawrence Livermore National Lab, and founder and chief scientific officer of Invenux.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.